Roux en Y gastric bypass surgery is a common cause

Roux-en-Y gastric bypass surgery is a common cause of malabsorption associated with hyperoxaluria in obese patients and those with malignancies. Postoperatively, patients may have steatorrhea, weight loss, and diarrhea, resulting in malabsorption syndrome, which would increase excessive intraluminal free fatty acid and bile salt. In the physiological condition, the oxalate would bind with calcium and be excreted in the stool. With the binding of calcium and fatty acid, it would cause further excessive Oprozomib molecular of oxalate from the gut. Additionally, it may further cause nephrolithiasis and nephrocalcinosis. One study indicated that obese patients who have undergone Roux-en-Y bypass surgery have a significantly higher incidence of nephrolithiasis compared to those in the control group (7.6 versus 4.6%, P < 0.0001). Similarly, patients with malignancies also have significantly higher postoperative nephrolithiasis and renal dysfunction after Roux-en-Y reconstruction surgery. Currently, effective treatments for hyperoxaluria are not yet feasible. Chemotherapy-induced nephrotoxicity, but not other etiologies, is usually considered to be the major cause of acute kidney injury in patients receiving chemotherapeutic agents. In angina case, although an uncommon disease, oxalate nephropathy is the etiology responsible for the acute kidney injury. It usually occurs 3–24 months after completion of the Roux-en-Y procedure, with an outcome that is typically dismal. One study has suggested that 72.7% of patients with oxalate nephropathy progress to end-stage kidney disease within 3 months.
Conflict of interest